MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

1.22B

Vuru Grade

31.00/100

Current Price

$21.77
+0.50 (+2.35%)

Stability Price

$1.36
Overvalued by 93.77%

Company Metrics

  • 13.83 P/E
  • 23.91 P/S
  • 5.52 P/B
  • -1.78 EPS
  • -5.97% Cash ROIC
  • 8.05 Cash Ratio
  • 0 / N/A % Dividend
  • 1.22M Avg. Vol.
  • 56.04M Shares
  • 1.22B Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Why Momenta Pharmaceuticals (MNTA) Could Be a Potential Winner
Zacks.com - 4 hours ago
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Momenta Pharmaceuticals Inc. (MNTA - Analyst Report). This biomedicine stock has actually seen estimates rise over the past month for the ...
Today's Dead Cat Bounce Stock Is Momenta Pharmaceuticals (MNTA) - TheStreet.com
Stocks to Keep Your Eyes on - Momenta Pharmaceuticals, Inc. (MNTA), AMN ... - Investor Wired
Here's Why Momenta Pharmaceuticals, Inc. Shares Took Off Today
Motley Fool - Jun 1, 2015
What's Happening: Shares in Momenta Pharmaceuticals (NASDAQ:MNTA) increased by 10% earlier today on news that the company is presenting updated clinical trial date for its pancreatic cancer therapy at the ASCO conference in Chicago. Why It's ...
Warning Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) optimists! Bruce ... - OctaFinance.com
Momenta Pharmaceuticals Inc. (MNTA) Has Surged To A New High For The Year - Nasdaq
UBS Securities Increases Momenta Pharmaceuticals (NASDAQ:MNTA)'s Stock ...
OctaFinance.com - 6 hours ago
Momenta Pharmaceuticals (NASDAQ:MNTA) traded down -5.17% on 7 March, hitting $21.27. A total of shares of the company's stock traded hands. This is down from average of 1.09M shares. Momenta Pharmaceuticals has a 52 week low of $9.38 and a 52 ...
Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Motley Fool - Apr 16, 2015
What: Momenta Pharmaceuticals (NASDAQ:MNTA) shares jumped by more than 10% earlier today following news that the FDA had approved Novartis' (NYSE:NVS) and Momenta's biosimilar to Teva Pharmaceuticals (NYSE:TEVA) Copaxone. So What: ...
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM ... - GlobeNewswire (press release)
FDA approves generic version of Teva's Copaxone, the most-used MS drug in ... - Fox Business
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) in Spotlight
Street Report - Jun 22, 2015
[Globe Newswire] Momenta Pharmaceuticals Inc (NASDAQ:MNTA)(TREND ANALYSIS) announced that Sandoz has initiated its U.S. launch of once daily Glatopa(TM) (glatiramer acetate injection), a generic equivalent of daily COPAXONE(R) 20 mg, ...
Why James Roach Unloaded 25000 Shares of Momenta Pharmaceuticals, Inc ... - OctaFinance.com
Analyst Upgrades: Red Hat, Inc., Momenta Pharmaceuticals, Inc., and First ... - Schaeffers Research (blog)
Michael Franken Sold 512 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ ...
OctaFinance.com - Jun 15, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 23.61 +0.63 2.74% 's President - Biosimilars Busines, Michael Franken, made a sale of 512 shares of stock in the -listed Momenta Pharmaceuticals Inc. The shares average cost was $22.4, for aggregate ...
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Sees Large Inflow ... - Insider Trading Report
Analyst Price Target Update on Momenta Pharmaceuticals, Inc.
Money Flow Index - Jul 2, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA): The mean estimate for the short term price target for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) stands at $21.17 according to 6 Analysts. The higher price target estimate for the stock has been ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst Rating Update - American Trade Journal
CFO Moves: Dollar General, IAC/InterActiveCorp, Momenta Pharmaceuticals
Wall Street Journal (blog) - Jun 25, 2015
Dollar General Corp.DG -2.10%, a Goodlettsville, Tenn., discount retailer, named John Garratt interim chief financial officer, effective July 1. Mr. Garratt is a senior vice president of finance and strategy at the company. He will succeed David Tehle ...
Stock Analysts Update on Momenta Pharmaceuticals Inc (NASDAQ:MNTA)
Markets Wired - Apr 17, 2015
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) price target raised to $24 from $16 at Leerink. Leerink raised its price target for Momenta Pharma to $24 following the “much anticipated” approval of generic Copaxone.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA FDA had approved Novartis ... - Inside Trade
James M. Roach Sells 50000 Shares of Momenta Pharmaceuticals Stock (MNTA) - WKRB News
Momenta Pharmaceuticals Inc. (MNTA): New Analyst Report from Zacks Equity ...
Nasdaq - Feb 4, 2015
Cambridge, MA-based Momenta Pharmaceuticals, Inc. is a biotechnology company focused on designing products on the basis of a complex systems analysis platform, analyzing data to assess the biological function of these products and developing ...